Shots:
- Gilead has entered into a definitive agreement to acquire Tubulis, making it an ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation
- As per the deal, Gilead will acquire Tubulis for $3.15B upfront & ~$1.85B in contingent milestone payments; closing is expected in Q2’26
- Acquisition will expand Gilead’s ADC capabilities by adding next-generation assets & platforms, incl. a P-Ib/II asset, TUB-040 (NaPi2b-directed TOPO1i ADC) for Pt-resistant ovarian cancer & NSCLC, & TUB-030 (5T4 targeted ADC) for various solid tumors
Ref: Gilead | Image: Tubulis | Press Release
Related News: Gilead to Acquire Ouro Medicine for ~$2.1B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
